News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck KGaA’s Erbitux Gets Green Light for Head Cancer
October 24, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
FRANKFURT, Oct 24 (Reuters) - A committee of experts advising the European Commission said on Friday it backed Merck KGaA's Erbitux drug for a second use to combat head and neck cancer, bolstering its sales potential in the region.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
FDA
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug
October 20, 2025
·
2 min read
·
Heather McKenzie
Approvals
Novo Secures Cardiovascular Expansion for Semaglutide Pill
October 20, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Hands Out First Commissioner’s Priority Vouchers to Regeneron, Sanofi, Disc, Others
October 17, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
In Affordability Push, EMD Serono Joins TrumpRx While Roche Launches DTC Program
October 17, 2025
·
2 min read
·
Tristan Manalac
